Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Patients with hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancers have the lowest response to neoadjuvant therapy of all subtypes. The role of neoadjuvant endocrine therapy (NET) in clinically node-positive (cN+), HR+, HER2- patients is evaluated in this meta-analysis.
Methods: This study was performed between January 2010 and August 2022. We evaluated the node pathologic complete response (pCR) and axillary lymph node dissection (ALND) rates after neoadjuvant endocrine therapy (NET).
Results: 18,037 HR+, HER2-, cN+ stage II and stage III breast cancer patients within eleven studies received neoadjuvant treatments. 3,707 (20.6%) patients received NET and 14,330 (79.4%) received NAC. The average age of the NET patients was higher than that of the neoadjuvant chemotherapy (NAC) patients (64.1 versus 47.6 years old, < 0.001). 45.0% and 26.9% of the NET and the NAC groups underwent a lumpectomy. The pooled estimates of node pCR in NET and NAC groups were 8.9% and 14.9%, and the pooled proportion of ALND was 39.1% and 58.5%, respectively.
Conclusion: The rate of node pCR was lower among cN+ patients who received NET compared to the NAC group. The rate of ALND among cN+ NET patients was lower than the NAC group, revealing more patients with residual nodal disease do not get ALND in the NET group. Further prospective studies are required to compare survival outcomes as a more reliable surrogate.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11315960 | PMC |
| http://dx.doi.org/10.1155/2024/8866756 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Novel Approach for Cisplatin-Resistant Esophageal Squamous Cell Carcinoma via Amino Acid Transporter LAT1 Inhibition.
Cancer Med
September 2025
Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Background: Esophageal squamous cell carcinoma (ESCC) represents an aggressive cancer type associated with poor prognosis, often treated with neoadjuvant chemotherapy (NAC) using cisplatin-based regimens. However, cisplatin resistance limits therapeutic efficacy, necessitating a deeper understanding of resistance mechanisms. L-type amino acid transporter 1 (LAT1) plays a crucial role in amino acid uptake and is linked to cancer cell survival through activation of the mammalian target of rapamycin (mTOR) pathway.
View Article and Find Full Text PDFDouble trouble, managing bilateral inflammatory breast cancer: a case report.
Front Oncol
August 2025
Department of Medical Oncology, Catalan Institute of Oncology, Dr. Josep Trueta University Hospital, Girona, Spain.
Inflammatory breast cancer (IBC) is a rare and aggressive breast cancer type, accounting for 5-7% of breast cancer-related deaths, and its bilateral involvement is exceedingly uncommon. We report a case of metachronous bilateral IBC in a 50-year-old premenopausal woman with Charcot-Marie-Tooth disease, offering novel insight into the diagnostic, therapeutic, and molecular challenges of this condition. The patient initially presented with acute right breast erythema, skin thickening, and , followed by contralateral breast involvement with similar symptoms.
View Article and Find Full Text PDFRecurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy?
Ann Surg Oncol
September 2025
Division of Endocrine and Oncologic Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Background: Interest in evaluating neoadjuvant immunotherapy for stage IIB/IIC melanoma is growing, but studies assessing long-term outcomes generally report data based on pathologic stage after sentinel lymph node microstaging. This study therefore aimed to characterize real-world recurrence patterns and survival specifically in clinical stage IIB/IIC melanoma to contextualize outcomes for selection of patients to undergo neoadjuvant immunotherapy.
Methods: This single-institution retrospective cohort study included patients who received a diagnosis of American Joint Committee on Cancer eighth-edition clinical stage IIB/IIC cutaneous melanoma from 2006 to 2019.
Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer.
Endocr Relat Cancer
September 2025
Kyoto Breast Cancer Research Network, Japan.
The addition of a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor to endocrine therapy augments biological response in breast cancer. This phase III randomized, double-blind study evaluated the efficacy of adding palbociclib to neoadjuvant endocrine therapy (NET) for operable, hormone receptor-positive human epidermal growth factor receptor-2 (HER2)-negative breast cancer. Patients randomly received 16 weeks of endocrine therapy (letrozole for post-menopausal and tamoxifen plus ovarian function suppression for pre/peri-menopausal patients) plus palbociclib or placebo.
View Article and Find Full Text PDFCastleman disease with synchronous primary rectal and prostate cancers: a case report of successful multimodal treatment and 2-year recurrence-free survival.
Front Oncol
August 2025
Department of Radiation Oncology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
Background: Castleman disease (CD) is a rare lymphoproliferative disorder associated with immune dysregulation that may increase the risk of malignancy. Synchronous multiple primary cancers are uncommon, and their etiology remains largely unclear. The coexistence of CD with synchronous multiple primary malignancies is exceptionally rare; therefore, the underlying mechanisms and optimal treatment strategies deserve further investigation.
View Article and Find Full Text PDF